Governance
Certified Special Committee for Regenerative Medicine
HOME
>
Governance
>
Certified Special Committee
Regenerative medicine reviewed fairly and rigorously, from medical, scientific, legal and bioethical perspectives.
Contents
01
About the Committee
02
Members
03
How a review proceeds
04
Disclosure
Contents
01
About the Committee
03
How a review proceeds
02
Members
04
Disclosure
Overview
About the Committee
The Advalife Science Certified Special Committee for Regenerative Medicine is certified by the Minister of Health, Labour and Welfare under the Act on the Safety of Regenerative Medicine.
Its purpose is to review regenerative medicine provision plans and related matters fairly and rigorously, from medical, scientific, legal and bioethical perspectives, and so to contribute to the safe and proper provision of regenerative medicine.
Name
Advalife Science Certified Special Committee for Regenerative Medicine
Certification number
NA8230001
Type of certification
Certified Special Committee for Regenerative Medicine
Valid until
7 July 2026 to 6 July 2029
Established by
General Incorporated Association Advalife Science
Address
Shingin-2 Bldg. 6F, 2-7-6 Ginza, Chuo-ku, Tokyo 104-0061, Japan
Scope of review
The Committee reviews Class I and Class II regenerative medicine provision plans and related matters against the standards for the provision of regenerative medicine and the other applicable laws and regulations.
What falls within the scope of review is determined by the terms of the certification and by the applicable laws and regulations.
Committee Composition
Members（Updated April 9, 2026）
Category
Name
Affiliation and Title
Gender
Abe Masatomo
Advalife Science, Representative Director
Male
Yamamoto Yohei
Association of Dementia Asset Consultants, Director
Visiting Researcher, Breast Surgery, Kyoto University Hospital
Male
Uto Yoshihiro
Professor, Division of Bioscience and Bioindustry, Graduate School of Technology, Industrial and Social Sciences, Tokushima University
Program-Specific Professor, Department of Healthy Aging, Graduate School of Medicine, Kyoto University
Male
Kaneda Munehisa
Research Lecturer, Department of Minimally Invasive Surgery Applying Regenerative Medicine, Juntendo University
Rene Medical Corporation, Chairperson and Chief Physician for Regenerative Medicine
ONODERA Medical, Chief Medical Officer (CMO)
(Medical Doctor)
Male
Umeda Masaru
Professor Emeritus, Tokyo University of Technology
Umena-no-Sato Geriatric Health Services Facility, Seiwakai Social Welfare Corporation
Advalife Science, Outside Director
Visiting Professor, Department of Medicine, Kurume University School of Medicine
(Medical Doctor)
Male
Kokuho Toshiharu
Vice Director, Department of Nephrology, Yokosuka City Hospital
Advalife Science, Outside Director
(Medical Doctor)
Male
Masumoto Takahito
SHI Co., Ltd., Regenerative Medicine Division
Male
Takaura Ayana
Manufacturing Department, I Peace, Inc.
Female
Murakami Yumie
Attorney at Law, Fukuyoshizaka Law Office
Female
Kawahara Naoto
Head of the Division of Ethics / Research Lecturer, Center for Clinical and Translational Research, Kyushu University Hospital
Male
Nishimura Chiaki
Representative, CN Medical Research
Male
Iida Yukino
Biostatistics Office, Data Science Division, Center for Innovative Clinical Medicine, Okayama University Hospital
Female
Izu Mitsutaka
President and Representative Director, ASP Co., Ltd.
General Manager of Sales, NK Estate Group
Male
Watanabe Ai
AEON Retail Co., Ltd.
Male
“Category” refers to the membership requirements set out in the Enforcement Regulations of the Act on the Safety of Regenerative Medicine.
This list is current as at 9 April 2026. For the current list of members, please see the Committee’s own website and the information published by the Ministry of Health, Labour and Welfare on “e-Rege”.
Where review business concerns a Class I or Class II regenerative medicine provision plan, it is conducted on the condition that members with no interest in the submitting healthcare institution (including bodies closely related to it) make up a majority of those present.
Romanised names and English renderings of affiliations are provisional and pending confirmation.
Presentations
学会発表
年
0000年
0000年
演題
演題が入ります
演題が入ります
学会
学会名
学会名
Review Process
How a review proceeds
STEP 01
Request and submission
The regenerative medicine provision plan and the documents required for review are submitted.
STEP 02
Committee review
The plan is reviewed against the standards for the provision of regenerative medicine and the other applicable laws, from medical, scientific, legal and bioethical perspectives.
STEP 03
Findings and opinion
On the basis of the review, the Committee gives its opinion on whether the treatment may properly be provided and on the points to be observed in providing it.
STEP 04
Records and disclosure
Records of the review and the other information the law requires to be made public are recorded and published in the prescribed manner.
Transparency & Disclosure
Transparency and disclosure
To keep the Committee’s work transparent, we publish the list of members, the rules governing the review process, records of that process, and the other information the applicable laws require to be made public.
For details, see the Committee’s own website and the information published on e-Rege, the database of the Ministry of Health, Labour and Welfare.
Independence & Conflict of Interest
The Committee operates according to the composition and quorum requirements set out in the applicable laws. To keep its reviews impartial, it manages conflicts of interest and everything else bearing on the independence of its work.
The Committee carries out reviews under the Act on the Safety of Regenerative Medicine. Its role is kept separate from that of the Advalife Science research and development division, which conducts drug discovery research, develops medicines and evaluates products and technologies.
QUALITY & GOVERNANCE
Contact us
If anything is unclear, our team will be glad to help.